[go: up one dir, main page]

MD20150076A2 - Metodă de tratament al fibrozei şi cancerului - Google Patents

Metodă de tratament al fibrozei şi cancerului Download PDF

Info

Publication number
MD20150076A2
MD20150076A2 MDA20150076A MD20150076A MD20150076A2 MD 20150076 A2 MD20150076 A2 MD 20150076A2 MD A20150076 A MDA20150076 A MD A20150076A MD 20150076 A MD20150076 A MD 20150076A MD 20150076 A2 MD20150076 A2 MD 20150076A2
Authority
MD
Moldova
Prior art keywords
cancers
fibrosis
treatment
carboxydimethylmethyloxyphenyl
methylthiophenyl
Prior art date
Application number
MDA20150076A
Other languages
English (en)
Russian (ru)
Other versions
MD4629B1 (ro
Inventor
Реми Анф
Хам
Роберт Вальчак
Бенуа Ноэль
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MD20150076A2 publication Critical patent/MD20150076A2/ro
Publication of MD4629B1 publication Critical patent/MD4629B1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prezenta invenţie se referă la utilizarea compusului 1-[metiltiofenil]-3-[3,5-dimetil-4-carboxidimetilmetiloxifenil]prop-2-en-1-onă pentru tratamentul bolilor fibrotice şi cancerului.
MDA20150076A 2013-01-18 2014-01-20 Metode de tratament a fibrozei şi cancerului MD4629B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305067 2013-01-18
PCT/EP2014/051060 WO2014111584A1 (en) 2013-01-18 2014-01-20 Methods of treatment of fibrosis and cancers

Publications (2)

Publication Number Publication Date
MD20150076A2 true MD20150076A2 (ro) 2015-11-30
MD4629B1 MD4629B1 (ro) 2019-05-31

Family

ID=47628079

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150076A MD4629B1 (ro) 2013-01-18 2014-01-20 Metode de tratament a fibrozei şi cancerului

Country Status (26)

Country Link
US (2) US20150352065A1 (ro)
EP (1) EP2948137B1 (ro)
JP (1) JP6218854B2 (ro)
KR (1) KR102196277B1 (ro)
CN (1) CN105120855B (ro)
AU (1) AU2014206781B2 (ro)
CA (1) CA2897258C (ro)
CY (1) CY1121156T1 (ro)
DK (1) DK2948137T3 (ro)
EA (1) EA031718B1 (ro)
ES (1) ES2702038T3 (ro)
HK (1) HK1214773A1 (ro)
HU (1) HUE042569T2 (ro)
IL (1) IL239715B (ro)
LT (1) LT2948137T (ro)
MD (1) MD4629B1 (ro)
MX (1) MX361565B (ro)
NZ (1) NZ709420A (ro)
PH (1) PH12015501566B1 (ro)
PL (1) PL2948137T3 (ro)
PT (1) PT2948137T (ro)
SG (1) SG11201505281PA (ro)
SI (1) SI2948137T1 (ro)
TR (1) TR201819042T4 (ro)
WO (1) WO2014111584A1 (ro)
ZA (1) ZA201505151B (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042569T2 (hu) 2013-01-18 2019-07-29 Genfit Rákok és fibrózis kezelési eljárások
WO2017147276A1 (en) * 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
CA3057940A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
EP3830070A1 (en) 2018-08-03 2021-06-09 Genfit Elafibranor salts
GB201901507D0 (en) * 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
BR112022015807A2 (pt) 2020-02-10 2023-03-14 Genfit Polimorfos de elafibranor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051465A1 (en) * 2001-06-20 2008-02-28 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
HUE042569T2 (hu) 2013-01-18 2019-07-29 Genfit Rákok és fibrózis kezelési eljárások

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051465A1 (en) * 2001-06-20 2008-02-28 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Also Published As

Publication number Publication date
EA201591345A1 (ru) 2015-11-30
US20150352065A1 (en) 2015-12-10
MX2015009251A (es) 2015-10-15
PL2948137T3 (pl) 2019-02-28
JP2016506913A (ja) 2016-03-07
HK1214773A1 (zh) 2016-08-05
CY1121156T1 (el) 2020-05-29
CA2897258C (en) 2021-02-02
HUE042569T2 (hu) 2019-07-29
IL239715A0 (en) 2015-08-31
AU2014206781B2 (en) 2018-08-23
KR102196277B1 (ko) 2020-12-29
CA2897258A1 (en) 2014-07-24
US20170239213A1 (en) 2017-08-24
ES2702038T3 (es) 2019-02-27
ZA201505151B (en) 2016-07-27
SI2948137T1 (sl) 2019-01-31
KR20150114497A (ko) 2015-10-12
US10792277B2 (en) 2020-10-06
CN105120855B (zh) 2019-05-07
TR201819042T4 (tr) 2019-01-21
PH12015501566B1 (en) 2018-10-26
NZ709420A (en) 2020-04-24
PH12015501566A1 (en) 2015-09-21
LT2948137T (lt) 2018-12-27
EA031718B1 (ru) 2019-02-28
MD4629B1 (ro) 2019-05-31
MX361565B (es) 2018-12-11
CN105120855A (zh) 2015-12-02
EP2948137B1 (en) 2018-11-14
PT2948137T (pt) 2018-12-20
AU2014206781A1 (en) 2015-07-16
IL239715B (en) 2019-06-30
DK2948137T3 (en) 2019-01-07
SG11201505281PA (en) 2015-08-28
JP6218854B2 (ja) 2017-10-25
EP2948137A1 (en) 2015-12-02
WO2014111584A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
PH12018502056B1 (en) Methods of treatment of cholestatic diseases
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
MY198017A (en) Anti-tigit antibodies
TW201613901A (en) New compounds
WO2015073587A3 (en) Synthetic membrane-receiver complexes
IL239981B1 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
PH12015502075A1 (en) Treatment of cataplexy
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
PH12017500864A1 (en) Anti-notch1 antibodies
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
PH12015501566A1 (en) Methods of treatment of fibrosis and cancers
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
PH12017501872A1 (en) Methods of treating diseases
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
EA201690170A1 (ru) Композиции и способы для лечения инсульта
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
IN2013MU03429A (ro)

Legal Events

Date Code Title Description
FC9A Refusal of application (patent for invention)
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)